NEWS

NEWS

Company News

Industry News

2025-07-24

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.
Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration.

MORE

2025-07-16

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a marketing authorization approval letter for midazolam injection from the French National Agency for the Safety of Medicines and Health Products (ANSM).

MORE

2025-06-19

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group
On June 12, Shi Dai, General Manager of China Merchants Group, conducted a field research on Renfu Pharmaceutical Group in Yichang, listened to a briefing, conducted an on-site inspection of its core subsidiary, Yichang Renfu, and gave important work instructions. Wu Bo, Chief Accountant of China Merchants Group; relevant department heads of China Merchants Group; and representatives from related enterprises including China Merchants New Materials, China Merchants Bank, China Changjiang Navigation, China Merchants Transportation, and China Merchants Shekou participated in the research.

MORE

Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials

Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of RFUS-949 tablets for the treatment of acute and chronic pain. This product is a new molecular entity drug developed by Yichang Renfu, classified as Class 1 chemical drug for registration, and there are no similar products approved for marketing in China.

06

2025/06

Hubei's first liquid formula food, "Te Yi Bei", produced by Yichang Renfu, has been approved for market launch.

Hubei's first liquid formula food, "Te Yi Bei", produced by Yichang Renfu, has been approved for market launch.

Recently, Yichang Renfu Pharmaceutical's subsidiary, Yichang Renfu TeYi Food Co., Ltd., received the "Registration Certificate for Special Medical Purpose Formula Foods" issued by the State Administration for Market Regulation. The company's developed special medical purpose liquid formula food "TeYiBei" has been approved for marketing (registration number: Guoshi Zhu Zi TY20250018). This is the first liquid formula food approved in Hubei Province.

12

2025/05

Yichang Renfu Pharmaceutical's valaciclovir hydrochloride tablets have passed the consistency evaluation for a new specification.

Yichang Renfu Pharmaceutical's valaciclovir hydrochloride tablets have passed the consistency evaluation for a new specification.

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received an Approval Notice for Supplemental Application of Drugs from the National Medical Products Administration (NMPA), approving the addition of a 0.5g specification for its valacyclovir hydrochloride tablets. This specification has also passed the consistency evaluation of quality and efficacy of generic drugs.

21

2025/04

Yichang Renfu Pharmaceutical's Esketamine Hydrochloride Injection has been approved for an additional clinical indication.

Yichang Renfu Pharmaceutical's Esketamine Hydrochloride Injection has been approved for an additional clinical indication.

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice for Esketamine Hydrochloride Injection from the National Medical Products Administration, agreeing to conduct clinical trials of the product for depression with acute suicidal ideation or behavior.

01

2025/04

Yichang Renfu Pharmaceutical's Lumiracoxib Capsules (Toluene Sulfonate) Approved for Clinical Trials

Yichang Renfu Pharmaceutical's Lumiracoxib Capsules (Toluene Sulfonate) Approved for Clinical Trials

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the conduct of clinical trials of lumeperone tosylate capsules for adult schizophrenia. This product is classified as a Class 3 chemical drug, and currently there are no similar products on the market in China.

31

2025/03

Yichang Renfu Pharmaceuticals Approved to Market Micafungin Sodium for Injection

Yichang Renfu Pharmaceuticals Approved to Market Micafungin Sodium for Injection

Recently, Yichang Renfu Pharmaceutical Company received the Certificate of Registration of Drugs approved and issued by the State Drug Administration, approving the listing of Micafungin Sodium for Injection.

17

2024/06

Yichang Renfu Ranked Top 8 in China's Brand Value Pharmaceutical and Healthcare Group

Yichang Renfu Ranked Top 8 in China's Brand Value Pharmaceutical and Healthcare Group

Recently, "2023 China Brand Value Evaluation Activity" initiated by China Brand Building Promotion Association, China Asset Appraisal Association and other organizations released the final evaluation results in Deqing, Zhejiang Province, and Yichang Renfu Pharmaceutical ranked eighth in the pharmaceutical and health group, with a brand strength of 884 and a brand value of 9.54 billion yuan, which was again improved by two places compared with the previous year. The brand value is 9.54 billion yuan, which is upgraded again compared with the previous year.

17

2024/06

Yichang Renfo Pharmaceuticals Remifentanil Approved in India

Yichang Renfo Pharmaceuticals Remifentanil Approved in India

Recently, Yichang Renfo Pharmaceuticals has obtained the marketing approval of remifentanil hydrochloride for injection (1mg, 2mg) from India's Central Drugs Standard Control Council (CDSCO), which is the company's first anesthetic injectable preparation that has completed clinical trials in India and has been approved according to the new drug standard.

14

2024/06